Thanks for sharing the email with us Mate. I believe was the first time they answer very quickly. We will be there Mate, I'm really sure. The only question is "when"... lol Good luck to you Mate, Obelix
Cheers mate, me too and I I'm sure that will be even more reinforced in the coming months...
What is a shame from Paul's reply is where he says that the companies don't want the competitors to find out and as such doesn't disclose for this reason.... It's understandable but a shame because the competitors finding out would no doubt be good for PYC ... If one major is using the tech then no doubt others would quickly follow suit... Sounds like the majors as they are pulling the money strings are also pulling the terms....
Let's just hope that whatever money they are splashing out on our tech is worth the company keeping quiet about... I'm sure it will be!
Mark Chadwick passed your e mail to me. We are not permitted under AIM rules to provide information to individual shareholders that is not already in the public domain. If we did, you for example would become an insider and if you traded using that knowledge you would commit an illegal act.
Client companies invariably do not permit us to disclose their names since the fact that they chose to use PYC models to aid development of their drugs would be valuable information to competitors. We have no choice in the matter. The same is true when it comes to disclosing the value of a contract. Again, more valuable intelligence to competitors.
The cost of the process to make an open offer to all investors relative to the likely investment received makes the process unaffordable. The YA deal is light on legal costs and we can execute a placement at very minimal discount to the market price. If we do an open offer, which would be mainly funded by broker/VC investors then the discount is considerably higher. The YM deal leads to minimal dilution for shareholders.
I realise that my answers leave many questions unanswered but given the limitations set out above, this is the best I can.
Paul Harper ""
Nothing we didn't already know but still nice to receive a reply ...
Ralph - yes YA making an un tidy exit.
PYC's time will come sooner rather then later i'm sure :-) have a good evening all.
As mentioned before, no details have been published if Physiomics have been in collaboration with Eli-Lilly with ramucirumab. Also, if Physiomics had been involved, it is not known if they will receive any revenue since the product going onto the market. DYOR.
Sounds like a plan to me mate... any profit i make in the near term will be coming in here as i'm expecting big things over the coming months. Just a case of sit tight and wait and see. mines a whiskey on the rocks ;-)
Yeah I read your message on the TGL board and decided to have a small punt mainly for the extra interest while some of my other holdings are not doing anything exciting (well exciting on the positive).
If either come off I will probably need to get the beer in. If not then hey one can only try to spot the next big thing lol
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.